|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200065494 |
|
最近更新日期: Date of Last Refreshed on: |
2022-11-07 12:44:57 |
|
注册时间: Date of Registration: |
2022-11-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
小剂量艾司氯胺酮用于防治剖宫产患者PPD的临床研究 |
|
Public title: |
A clinical study of low-dose esketamine for the prevention and treatment of PPD in patients undergoing cesarean section |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
小剂量艾司氯胺酮用于防治剖宫产患者PPD的临床研究 |
|
Scientific title: |
A clinical study of low-dose esketamine for the prevention and treatment of PPD in patients undergoing cesarean section |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
任力 |
研究负责人: |
吴刚明 |
|
Applicant: |
Li Ren |
Study leader: |
Gangming Wu |
|
申请注册联系人电话: Applicant telephone: |
18323187421 |
研究负责人电话:
Study leader's |
18323187421 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
459910606@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
459910606@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市渝中区袁家岗友谊路1号 |
研究负责人通讯地址: |
重庆市渝中区袁家岗友谊路1号 |
|
Applicant address: |
No.1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
Study leader's address: |
No.1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
重庆医科大学附属第一医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Chongqing Medical University |
||
|
研究负责人所在单位: |
重庆医科大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Chongqing Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022年科伦药审(20223102)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆医科大学附属第一医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First Affiliated Hospital of Chongqing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-09-26 00:00:00 | ||
|
伦理委员会联系人: |
严青 |
||
|
Contact Name of the ethic committee: |
Qing Yan |
||
|
伦理委员会联系地址: |
重庆市渝中区袁家岗友谊路1号 |
||
|
Contact Address of the ethic committee: |
The First Affiliated Hospital of Chongqing Medical University |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
重庆医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Chongqing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝中区袁家岗友谊路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
重庆市卫健委 |
||||||||||||||||||||||
|
Source(s) of funding: |
Chongqing Municipal Health Commission |
||||||||||||||||||||||
|
研究疾病: |
产后抑郁 |
||||||||||||||||||||||
|
Target disease: |
Postpartum depression |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过应用EPDS量表对患者不同时间段进行评分,观察艾司氯胺酮对剖宫产患者产后抑郁的预防作用,为临床防治产妇产后抑郁提供指导依据,同时采用NRS评分观察艾司氯胺酮对急慢性疼痛的疗效,并与产后抑郁发生进行相关性分析,为临床急慢性疼痛治疗和防治产后抑郁提供实践依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To observe the preventive effect of esketamine on postpartum depression in cesarean section patients by applying the EPDS scale to score patients at different time periods, and to provide guidance for clinical prevention and treatment of postpartum depression, and to observe the efficacy of esketamine on acute and chronic pain by using the NRS score, and to analyze the correlation with the occurrence of postpartum depression, so as to provide a practical basis for clinical treatment of acute and chronic pain and prevention of postpartum depression. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
年龄20~35周岁,因足月单胎妊娠拟在硬膜外阻滞下行剖宫产的孕妇,志愿加入本次研究并获得知情同意书者。 |
||||||||||||||||||||||
|
Inclusion criteria |
Pregnant women aged 20 to 35 years who were to undergo cesarean section under epidural block for full-term singleton pregnancy, volunteered to join this study and obtained informed consent. |
||||||||||||||||||||||
|
排除标准: |
既往有精神疾病史或家族史;完全型/部分型前置胎盘需全身麻醉的孕妇;存在硬膜外阻滞的禁忌症,包括凝血功能较差,穿刺部位感染,明显的腰椎损伤等;对局麻药过敏者;有严重的妊娠合并症者:如未良好控制的妊娠期高血压或糖尿病,合并了严重的心脏,肝脏,肾脏功能损伤者 |
||||||||||||||||||||||
|
Exclusion criteria: |
Previous history of mental illness or family history; pregnant women with complete/partial placenta praevia requiring general anesthesia; contraindications to epidural block, including poor coagulation, puncture site infection, significant lumbar spine injury, etc.; allergy to local anesthetics; severe pregnancy comorbidities, such as uncontrolled hypertension or diabetes mellitus during pregnancy, combined with severe cardiac, hepatic, and renal impairment |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-11-20 00:00:00至 To 2024-11-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-11-20 00:00:00 至 To 2024-12-20 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本试验采用电脑随机方式,研究者筛选出每一例合格受试者后登陆随机系统,填写受试者筛选资 料,获取随机号和相应的药物编号,药物管理员按照相应的药物编号信息进行药物的发放。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
In this trial, computerized randomization was used. After screening each eligible subject, the investigator logged into the randomization system, filled in the subject screening information, obtained the randomization number and the corresponding drug number, and the drug administrator administered the drug according to the |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
双盲 |
|
Blinding: |
double blind |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不采用网络平台公开原始数据,由研究者保存,若需要,可进一步提供。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
No web platform is used to disclose raw data, which are kept by the researcher and can be further provided if needed. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表(Case Record Form, CRF) |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |